January 26, 2021 Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space Explore further
October 2, 2020 ENZYCHEM LIFESCIENCES SELECTED TO PRESENT AT 2020 RADIATION RESEARCH SOCIETY ANNUAL MEETING Explore further
September 22, 2020 EC-18 COULD BE SOUTH KOREA’S NEXT GLOBAL BLOCKBUSTER DRUG BY KI YOUNG SOHN, CHAIRMAN OF ENZYCHEM LIFESCIENCES Explore further
August 13, 2020 ENZYCHEM LIFESCIENCES ANNOUNCES FDA ACCEPTANCE OF PHASE 2 STUDY OF EC-18 IN PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) DUE TO COVID-19 PNEUMONIA Explore further
July 14, 2020 ENZYCHEM LIFESCIENCES FILES IND APPLICATION TO FDA FOR PHASE 2 STUDY OF EC-18 IN PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) DUE TO COVID-19 PNEUMONIA Explore further
